Drugs.com - Monthly Update December 2025 скачать в хорошем качестве

Drugs.com - Monthly Update December 2025

This month, discover the Wegovy tablet, the first oral GLP-1 weight loss medication to be approved, Myqorzo's long-awaited treatment for obstructive hypertrophic cardiomyopathy, and several other exciting new FDA approvals. Explore these key stories and more in our December 2025 round-up. Wegovy (semaglutide) tablet, the first oral GLP-1 for weight loss, with significant efficacy in patient trials. https://www.drugs.com/wegovy.html Myqorzo (aficamten), a long-awaited and major addition to obstructive hypertrophic cardiomyopathy treatment that improves exercise capacity. https://www.drugs.com/myqorzo.html Exdensur (depemokimab-ulaa), a new long-term, add-on treatment for severe eosinophilic asthma with twice-yearly injections. https://www.drugs.com/exdensur.html Jaypirca (pirtobrutinib), a non-covalent BTK inhibitor whose approval has been extended to include chronic lymphocytic leukemia and small lymphocytic lymphoma. https://www.drugs.com/jaypirca.html Lerochol (lerodalcibep-liga), a third-generation, PCSK9 inhibitor for high cholesterol self-administered via a monthly injection. https://www.drugs.com/lerochol.html Breyanzi (lisocabtagene maraleucel), a CAR T cell therapy with extended approval to include relapsed or refractory marginal zone lymphoma. https://www.drugs.com/breyanzi.html Chapters 00:00 - Intro 00:22 - Overview 00:34 - Wegovy 01:16 - Myqorzo 02:07 - Exdensur 02:56 - Jaypirca 03:31 - Lerochol 04:09 - Breyanzi 04:46 - Outro Follow Drugs.com: X   / drugscom   Facebook   / drugscom   Signup to our newsletters https://www.drugs.com/newsletters/ Download the app https://www.drugs.com/apps/